HDAX Therapeutics

www.hdaxtx.com
Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
A blood-brain barrier permeable HDAC6 selective inhibitors for CNS cancers based on proprietary technology that unlocks novel binding mechanism for improved next-gen targeting.

Related news

FACIT portfolio company HDAX Therapeutics closes seed financing to target CNS cancers and neuropathies

FACIT congratulates HDAX Therapeutics (“HDAX”) on the closing of a seed financing round to develop their best-in-class HDAC therapeutics for the treatment of a serious cancer conditions. Capital from the investor group, which included an investment from FACIT’s Compass Rose Oncology Fund, will empower HDAX to address the debilitating neuropathic pain frequently experienced by patients with cancer. Read More

FACIT and OBIO® partner on women-focused seed capital and entrepreneurship program

On International Women’s Day, FACIT and OBIO® are pleased to announce a new partnership in the Ontario life sciences ecosystem, built on their common goal to drive entrepreneurial and commercialization mandates to address the unmet needs and barriers faced by female entrepreneurial leaders in STEM. Read More

FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.